Dose of Remi in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-10

Study Completion Date

2023-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Remimazolam has demonstrated the potential as a valuable medication for procedural sedation and general anesthesia. However, the effective dosage of remimazolam in pediatric patients is still unknown.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction

NCT06061159

Pediatric ED95 Sedation +1 more

COMPLETED PHASE4

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

NCT04851717

Pediatric ALL

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children

NCT06121609

Bidirectional Endoscopy

COMPLETED NA

Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children

NCT02519595

Moderate, Deep Sedation

COMPLETED PHASE4

Sedation MRI - Propofol Versus Propofol-Ketamin in Children

NCT01519154

Sedation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

remimazolam

remimazolam is given for anesthesia induction

Group Type EXPERIMENTAL

Remimazolam

Intervention Type DRUG

remimazolam is given intravenously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remimazolam

remimazolam is given intravenously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

remimazolam besylate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age from 3 to 12 years old
* patients scheduled for surgery under general anesthesia

Exclusion Criteria

* American Society of Anesthesiologists status \>=Ⅲ
* Body mass index\>=28kg/m2
* patients who cannot cooperate with intravenous anesthesia induction
* patients with risk of difficult airway
* patients who are allergic to benzodiazepines
* patients with delayed neurologic function

Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No